Biosimilar Medicinal Products Working Party
Submitted by Anonymous (not verified) on 4 February 2025 - 13:30
Biosimilar Medicinal Products Working Party
Biosimilar Medicinal Products Working Party
Cardiovascular Working Party
Central Nervous System Working Party
Human medicines European public assessment report (EPAR): Izelvay, avacincaptad pegol, Status: Application withdrawn
PSUSA/00000408/202405
Qualification of non-mutagenic impurities - Scientific guideline
Nanotechnology-based medicinal products for human use EU-IN Horizon Scanning Report
Committee for Advanced Therapies (CAT): Work Plan 2025
Human medicines European public assessment report (EPAR): Fortacin, lidocaine,prilocaine, Date of authorisation: 15/11/2013, Revision: 13, Status: Authorised
List of centrally authorised products with safety-related changes to the product information